MedTrace Logo

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2018-04-17

Study results available
· View outcomes & findings →

Summary

Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost

Conditions

Interventions

DRUG

AR-13324 Ophthalmic Solution 0.01%

Administered to study eye, once daily (QD) in the evening (PM) for 28 days

DRUG

AR-13324 Ophthalmic Solution 0.02%

Administered to study eye, QD in the PM for 28 days

DRUG

Latanoprost ophthalmic solution 0.005%

Administered to study eye, QD in the PM for 28 days

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Theresa Heah, MD · Aerie Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01731002 on ClinicalTrials.gov